LS 2616

Known as: LS-2616, LS2616 
 
National Institutes of Health

Topic mentions per year

Topic mentions per year

1986-2004
012319862004

Papers overview

Semantic Scholar uses AI to extract papers important to this topic.
1991
1991
The immunomodulator LS-2616 (Linomide) induces rejection of cyclosporine-protected rat cardiac allografts. The aim of this study… (More)
Is this relevant?
1989
1989
The quinoline-3-carboxamide, Linomide, has been shown to possess potent immunomodulatory activity. We have evaluated the effect… (More)
  • figure 1
  • figure 2
Is this relevant?
1989
1989
The effect of the quinoline-3-carboxamide LS-2616 (Linomide), given alone or together with cyclosporine, was studied in the first… (More)
Is this relevant?
1989
1989
In the current study we examine parameters affecting the metastasis of ocular tumors of in vivo derived B16F10 melanoma. In C57BL… (More)
  • table 1
  • table 2
  • table 3
  • table 5
  • table 6
Is this relevant?
1988
1988
In experiments using cultured cells, LS2616 has been shown to decrease growth of primary tumors and pulmonary metastasis of… (More)
  • table 1
  • figure 1
  • figure 2
  • table 2
Is this relevant?
1988
1988
The autoimmune MRL/Mp-lpr/lpr (MRL/l) mouse spontaneously develops sialadenitis with a morphological and phenotypical pattern… (More)
  • table 1
  • table 2
  • figure 1
  • table 3
Is this relevant?
1987
1987
Spleen cells from mice treated with LS2616 display a highly increased response to the polyclonal T cell lectin ConA. The total… (More)
Is this relevant?
1986
1986
The carboxamide-quinoline LS 2616 is a novel immunomodulator augmenting natural killer (NK) cell activity and T-lymphocyte… (More)
Is this relevant?
1986
1986
Autoimmune (NZB X NZW) F1 female hybrid mice were treated with LS-2616, a recently developed substance with immunomodulating… (More)
Is this relevant?
1986
1986
Autoimmune MRL/1 mice were treated with a recently developed substance with immunomodulating properties, LS-2616. Treatment was… (More)
Is this relevant?